Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

NCT05843643 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05843643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05843643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 25, 2023
Completion date
October 31, 2027
Enrollment
1,014 (actual)
Sites
369

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus